Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
June 02, 2022 08:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
May 19, 2022 08:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
May 12, 2022 07:00 ET
|
Larimar Therapeutics
- CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of...
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
March 25, 2022 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
February 14, 2022 16:01 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
November 15, 2021 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
November 12, 2021 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
September 16, 2021 08:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 02, 2021 16:01 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...